Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on KH631 gene therapy for neovascular age-related macular degeneration, focusing on safety and tolerability; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH631 gene therapy

Snippet

Sponsor: Chengdu Origen Biotechnology Co., Ltd. | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING